Current Vascular Pharmacology
Title:Foreword [ Current Vascular Pharmacology is 10 Years Old! ]
Volume: 10 Issue: 1
Author(s): Dimitri P. Mikhailidis
Affiliation:
Export Options
About this article
Cite this article as:
P. Mikhailidis Dimitri, Foreword [ Current Vascular Pharmacology is 10 Years Old! ], Current Vascular Pharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157016112798829841
DOI https://dx.doi.org/10.2174/157016112798829841 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Individual Triptan Selection in Migraine Attack Therapy
Recent Patents on CNS Drug Discovery (Discontinued) New Technologies for the Diagnosis of Sleep Apnea
Current Hypertension Reviews The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Biological Activities and Synthetic Approaches of Dihydropyrimidinones and Thiones - An Updated Review
Current Bioactive Compounds Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets Nanoparticle Based Treatment for Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Chronic Streptococcal and Non-Streptococcal Pharyngitis
Infectious Disorders - Drug Targets Which is the Optimal Antihypertensive Combination in Different Diseases, a Renin- Angiotensin-aldosterone System Inhibitor with a Diuretic or with a Calcium Channel Blocker?
Current Pharmaceutical Design Looming of Ecological Toxinology
Venoms and Toxins Current Status of Pharmacological Thrombolytic Therapy and Mechanical Thrombectomy for the Treatment of Acute Deep Venous Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets A New Gene Delivery System Based on Controlled Release Technology
Current Drug Delivery Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Editorial from Editor-in-Chief: Are Implanted Upper Airway Stimulation Devices for the Treatment of Obstructive Sleep Apnea Ready for Primetime?
Current Respiratory Medicine Reviews Obstetrical Hemorrhage Review
Current Women`s Health Reviews Editorial (Oxidative Stress in the Vascular Wall: A Useful Physiological Process or a Therapeutic Target in Vascular Disease?)
Recent Patents on Cardiovascular Drug Discovery Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Tissue-Specific Glucocorticoid Reactivating Enzyme, 11β-Hydroxysteoid Dehydrogenase Type 1 (11β-HSD1) - A Promising Drug Target for the Treatment of Metabolic Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders